Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
This article discusses the problems associated with the search of the most effective treatment strategies for HER2-negative metastatic breast cancer in premenopausal women. Until recently, ovarian suppression and hormone therapy had been the main treatments used in this group of patients. The develo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-09-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/646 |
| _version_ | 1797875994680360960 |
|---|---|
| author | E. V. Artamonova E. I. Kovalenko |
| author_facet | E. V. Artamonova E. I. Kovalenko |
| author_sort | E. V. Artamonova |
| collection | DOAJ |
| description | This article discusses the problems associated with the search of the most effective treatment strategies for HER2-negative metastatic breast cancer in premenopausal women. Until recently, ovarian suppression and hormone therapy had been the main treatments used in this group of patients. The development of palbociclib, called a “breakthrough therapy”, as well as promising results of trials evaluating the efficacy of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors added to hormone therapy in postmenopausal women suggested a need for the assessment of this treatment regimen in combination with ovarian suppression in younger patients.According to the results of randomized trials and subgroup analysis, the addition of a CDK4/6 inhibitor to ovarian suppression and hormonal therapy significantly increases survival. The safety profile is similar to that of older patients. Randomized trials comparing the efficacy of palbociclib + ovarian suppression + aromatase inhibitor vs. chemotherapy in premenopausal women demonstrated significant benefits of a new treatment strategy: a CDK4/6 inhibitor as a part of combination therapy reduced the risk of progression by 36 % compared to capecitabine. |
| first_indexed | 2024-04-10T01:56:17Z |
| format | Article |
| id | doaj.art-3fe9977803db4fb09e3b57b276621d7e |
| institution | Directory Open Access Journal |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| last_indexed | 2024-04-10T01:56:17Z |
| publishDate | 2019-09-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj.art-3fe9977803db4fb09e3b57b276621d7e2023-03-13T08:44:37ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272019-09-01152304110.17650/1994-4098-2019-15-2-30-41610Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitorsE. V. Artamonova0E. I. Kovalenko1ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииThis article discusses the problems associated with the search of the most effective treatment strategies for HER2-negative metastatic breast cancer in premenopausal women. Until recently, ovarian suppression and hormone therapy had been the main treatments used in this group of patients. The development of palbociclib, called a “breakthrough therapy”, as well as promising results of trials evaluating the efficacy of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors added to hormone therapy in postmenopausal women suggested a need for the assessment of this treatment regimen in combination with ovarian suppression in younger patients.According to the results of randomized trials and subgroup analysis, the addition of a CDK4/6 inhibitor to ovarian suppression and hormonal therapy significantly increases survival. The safety profile is similar to that of older patients. Randomized trials comparing the efficacy of palbociclib + ovarian suppression + aromatase inhibitor vs. chemotherapy in premenopausal women demonstrated significant benefits of a new treatment strategy: a CDK4/6 inhibitor as a part of combination therapy reduced the risk of progression by 36 % compared to capecitabine.https://ojrs.abvpress.ru/ojrs/article/view/646метастатический рак молочной железыпременопаузагормонотерапияингибиторы циклинзависимых киназ |
| spellingShingle | E. V. Artamonova E. I. Kovalenko Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors Опухоли женской репродуктивной системы метастатический рак молочной железы пременопауза гормонотерапия ингибиторы циклинзависимых киназ |
| title | Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors |
| title_full | Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors |
| title_fullStr | Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors |
| title_full_unstemmed | Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors |
| title_short | Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors |
| title_sort | hormone therapy for premenopausal women with metastatic breast cancer combinations with cyclin dependent kinase inhibitors |
| topic | метастатический рак молочной железы пременопауза гормонотерапия ингибиторы циклинзависимых киназ |
| url | https://ojrs.abvpress.ru/ojrs/article/view/646 |
| work_keys_str_mv | AT evartamonova hormonetherapyforpremenopausalwomenwithmetastaticbreastcancercombinationswithcyclindependentkinaseinhibitors AT eikovalenko hormonetherapyforpremenopausalwomenwithmetastaticbreastcancercombinationswithcyclindependentkinaseinhibitors |